- Home
- WATT vs CDT Comparison
WATT vs CDT Comparison
Compare WATT & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- CDT
- Stock Information
- Founded
- WATT 2012
- CDT 2019
- Country
- WATT United States
- CDT United States
- Employees
- WATT N/A
- CDT N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- CDT Health Care
- Exchange
- WATT Nasdaq
- CDT Nasdaq
- Market Cap
- WATT 10.0M
- CDT 11.1M
- IPO Year
- WATT 2014
- CDT N/A
- Fundamental
- Price
- WATT $0.48
- CDT $0.06
- Analyst Decision
- WATT Strong Buy
- CDT
- Analyst Count
- WATT 2
- CDT 0
- Target Price
- WATT $2.25
- CDT N/A
- AVG Volume (30 Days)
- WATT 18.4M
- CDT 104.2M
- Earning Date
- WATT 11-12-2024
- CDT 02-14-2025
- Dividend Yield
- WATT N/A
- CDT N/A
- EPS Growth
- WATT N/A
- CDT N/A
- EPS
- WATT N/A
- CDT N/A
- Revenue
- WATT $431,184.00
- CDT N/A
- Revenue This Year
- WATT $95.75
- CDT N/A
- Revenue Next Year
- WATT $834.07
- CDT N/A
- P/E Ratio
- WATT N/A
- CDT N/A
- Revenue Growth
- WATT N/A
- CDT N/A
- 52 Week Low
- WATT $0.28
- CDT $0.05
- 52 Week High
- WATT $2.75
- CDT $3.92
- Technical
- Relative Strength Index (RSI)
- WATT 46.32
- CDT 42.52
- Support Level
- WATT $0.49
- CDT $0.08
- Resistance Level
- WATT $1.44
- CDT $0.18
- Average True Range (ATR)
- WATT 0.22
- CDT 0.02
- MACD
- WATT -0.06
- CDT -0.00
- Stochastic Oscillator
- WATT 1.55
- CDT 0.41
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.